学会発表
Clinical efficacy of eribulin as a first- or second-line treatment for patients with recurrent HER2-negative breast cancer : a phase II randomized study (JBCRG-19)
Kenichi Watanabe, Kenjiro Aogi, Masahiro Kitada, Takafumi Sangai, Shoichiro Ohtani, Tomoyuki Aruga, Hidetoshi Kawaguchi, Tomomi Fujisawa, Shigeto Maeda, Takashi Morimoto, Satoshi Morita, Norikazu Masuda, Masakazu Toi, Shinji Ohno
2018.10 ESMO Poster Munich, Germany
Prospective observational cohort study of bevacizumab combined with paclitaxel as the first- or second-line chemotherapy for locally advanced or metastatic breast cancer (Study JBCRG-C05: B-SHARE)
Masahiro Kashiwaba, Yutaka Yamamoto, Hidetoshi Yamashiro, Naoto Kondo, Rikiya Nakamura, Masato Takahashi, Uhi Toh, Koichiro Tsugawa, Kazutaka Narui, Kentaro Tamaki, Tetsuhiro Yoshinami, Shoichiro Ohtani, Yuichiro Kai, Toshimi Takano, Yasuhiro Yanagita, Satoshi Morita, Masakazu Toi, Shinji Ohno
2018.3 EBCC Poster Barcelona, Spain
閉経後ER陽性進行・再発乳癌におけるフルベストラントの至適投与方法の検討（JBCRG-C06: Safari）
川口英俊、増田慎三、中山貴寛、青儀健二郎、阿南敬生、伊藤良則、大谷彰一郎、佐藤信昭、佐治重衡、徳永えり子、中村清吾、長谷川善枝、藤澤知巳、山口美樹、山下年成、山本豊、森田智視、大野真司、戸井雅和
第26回日本乳癌学会学術集会 Kyoto, JAPAN 2018年5月
TrastuzumabとPertuzumabの同時混合点滴の安全性に関する検討 (JBCRG-20 sub-study)
坂東裕子、増田慎三、伊藤良則、石田和茂、井口研子、水谷麻紀子、小林 心、柏葉匡寛、八十島宏行、笠井宏委、高須賀剛、森田智視、大野真司、戸井雅和
第26回日本乳癌学会学術集会 Kyoto, JAPAN 2018年5月
Evaluation of the safety of neoadjuvant endocrine therapy with exemestane followed by response-guided combination therapy with docetaxel and cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG-11TC)
Koji Kaneko, Nobuaki Sato, Hiroyuki Yasojima, Norikazu Masuda, Takashi Morimoto, Takayuki Ueno, Chizuko Kanbayashi, Shigehira Saji, Hironobu Sasano, Satoshi Morita, Shinji Ohno, Masakazu Toi
第56回日本癌治療学会学術集会 Yokohama, JAPAN 2018年10月
Predicting pathological complete response by the combination of microRNAs in patients with HER2-positive primary breast cancer who received neoadjuvant combination therapy of trastuzumab, lapatinib and paclitaxel: Results from JBCRG-16 (NeoLath) study.
Akihiko Shimomura, Norikazu Masuda, Junpei Kawauchi, Satoko Takizawa, Makiko Ichikawa, Juntaro Matasuzaki, Katsumasa Kuroi, Hisato Hara, Naohito Yamamoto, Kenichi Inoue, Nobuyasu Suganuma, Kenjiro Aogi, Shinji Ohno, Kenji Tamura, Takahiro Ochiya, Masakazu Toi
2018.12 SABCS Poster San Antonio, USA
A phase III trial to compare eribulin mesylate + trastuzumab (H) + pertuzumab (P) with paclitaxel or docetaxel + HP for HER2-positive advanced or metastatic breast cancer (JBCRG-M06 / EMERALD)
Norikazu Masuda, Toshinari Yamashita, Shigehira Saji, Kazuhiro Araki, Yoshinori Ito, Toshimi Takano, Masato Takahashi, Junji Tsurutani, Kei Koizumi, Masahiro Kitada, Yasuyuki Kojima, Yasuaki Sagara, Hiroshi Tada, Tsutomu Iwasa, Takayuki Kadoya, Tsuguo Iwatani, Hiroki Hasegawa, Satoshi Morita, Shinji Ohno
2018.12 SABCS Poster San Antonio, USA
Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 8-12 weeks’ exemestane exposure for ER+/HER2-postmenopausal breast cancer patients (JBCRG-11TC)
Hiroyuki Yasojima, Nobuaki Sato, Norikazu Masuda, Takashi Morimoto, Takayuki Ueno, Chizuko Kanbayashi, Koji Kaneko, Shigehira Saji, Hironobu Sasano, Satoshi Morita, Shinji Ohno, and Masakazu Toi
2018.12 SABCS Poster San Antonio, USA
Tailored neoadjuvant endocrine and chemo-endocrine therapy for postmenopausal patients with estrogen receptor-positive human epidermal growth factor receptor 2-negative primary breast cancer
Norikazu Masuda, Nobuaki Sato, Takashi Morimoto, Takayuki Ueno, Chizuko Kanbayashi, Koji Kaneko, Hiroyuki Yasojima, Shigehira Saji, Hironobu Sasano, Satoshi Morita, Shinji Ohno, Masakazu Toi
2017.12 SABCS poster San Antonio, USA
閉経後HR乳癌患者に対するレスポンスガイド下術前内分泌療法 (JBCRG-11CPA)
森本 卓，佐藤 信昭，増田 慎三，上野 貴之，神林智寿子、金子耕司、八十島宏行、佐藤 友威、新宮 聖士、田邊 匡、尾崎 慎治、笹野 公伸、森田 智視、大野 真司，戸井 雅和
2017年10月 第55回日本癌治療学会学術集会 ワークショップ